Business
Announcement on Voluntary Disclosure of the Acceptance of Drug Marketing Application for Obeticholic Acid Tablets for the Treatment of Primary Biliary Cholangitis
Announcement on Voluntary Disclosure of the Acceptance of Drug Marketing Application for Obeticholic Acid Tablets for the Treatment of Primary Biliary Cholangitis
About this update from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A
Announcement on Voluntary Disclosure of the Acceptance of Drug Marketing Application for Obeticholic Acid Tablets for the Treatment of Primary Biliary Cholangitis The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment